This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other ...
Antibody–drug conjugates have emerged as a powerful tool ... The drug linker is typically created as a peptide or carbohydrate that is cleaved inside the tumour cell after internalization ...
Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to ...
Sept. 16, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics ...
Oct. 07, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics ...
Scientists from China have investigated how short peptide chains aggregate together in order to deepen our understanding of ...
News Medical on MSN6mon
Revolutionizing cysteine-rich peptide production for drug discoveryCertain types of peptides and microproteins for drug discovery research can be made more efficiently and quickly using a ...
Oct. 07, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics ...
Register to read this story and more for free. Signing up for an account helps us improve your browsing experience.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback